Leqvio vs Lisinopril: Combining the Two (Rationale + Risk)

What Leqvio and Lisinopril Actually Do

These two drugs solve different problems. Leqvio (inclisiran) is a small-interfering RNA (siRNA) that binds to PCSK9 messenger RNA inside hepatocytes and prevents translation of the PCSK9 protein. Less PCSK9 means more LDL receptors remain on the liver surface, pulling LDL particles out of circulation. Lisinopril is a long-acting ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone release, which lowers blood pressure and reduces cardiac afterload.

Mechanism summary

Neither drug touches the other's primary pathway. Inclisiran is administered subcutaneously and is processed by the liver's endosomal machinery. Lisinopril is absorbed orally, acts on vascular endothelium and the kidney, and is excreted renally. There is no overlapping metabolic route, no shared CYP450 pathway, and no competitive protein binding between the two agents.

What each drug cannot do

Leqvio does not lower blood pressure in any clinically significant way, and lisinopril does not meaningfully reduce LDL-C. A patient with an LDL-C of 130 mg/dL and a blood pressure of 158/96 mmHg has two distinct problems that one drug cannot resolve. This is the core rationale for combination use.

Leqvio (Inclisiran): Evidence Summary

ORION-10 and ORION-11

The key registration trials for inclisiran were ORION-10 and ORION-11, both published in the New England Journal of Medicine in 2020. ORION-10 (N=1,561) enrolled patients with atherosclerotic cardiovascular disease (ASCVD) already on maximally tolerated statin therapy. At day 510, inclisiran 284 mg produced a mean placebo-corrected LDL-C reduction of 52.3%, compared with 49.9% in ORION-11 (N=1,617), which included patients with ASCVD or ASCVD-risk equivalents.

The time-averaged LDL-C reduction across both trials was approximately 50%, a figure that places inclisiran in the same efficacy tier as monoclonal PCSK9 inhibitors such as evolocumab and alirocumab, but with a twice-yearly dosing schedule rather than every two to four weeks.

Safety profile relevant to combination use

Injection-site reactions occurred in 2.6% of inclisiran patients versus 0.9% with placebo. Rates of serious adverse events, liver enzyme elevations, and renal events were similar between groups. Inclisiran is renally excreted, so renal impairment prolongs systemic exposure, but the drug's effect is confined to the liver and does not amplify ACE-inhibitor-mediated renal effects.

The FDA label for inclisiran carries no contraindication against concurrent ACE inhibitor use, and no dose adjustment is specified when lisinopril or any other ACE inhibitor is added.

Lisinopril: Evidence Summary

ALLHAT and the ACE inhibitor evidence base

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), published in JAMA in 2002 (N=33,357), remains the largest randomized hypertension outcomes trial ever conducted. Lisinopril was compared to chlorthalidone and amlodipine over a mean 4.9-year follow-up. The primary composite outcome of fatal coronary heart disease or nonfatal MI did not differ significantly between lisinopril and chlorthalidone (relative risk 1.00, 95% CI 0.94 to 1.08 for the combined CHD endpoint). Lisinopril did produce slightly higher rates of stroke and heart failure compared to chlorthalidone, driven partly by smaller systolic blood pressure reductions in Black patients.

The 2022 ACC/AHA Hypertension Guideline designates ACE inhibitors as first-line agents for hypertension in patients with chronic kidney disease, heart failure with reduced ejection fraction, and diabetes, all conditions that frequently co-exist with the hyperlipidemia that inclisiran targets.

Cardioprotective mechanisms beyond blood pressure

Lisinopril reduces left ventricular hypertrophy, slows diabetic nephropathy progression, and reduces proteinuria. In the SOLVD treatment trial (N=2,569), enalapril (a closely related ACE inhibitor) reduced mortality by 16% and heart failure hospitalizations by 26% in patients with reduced ejection fraction. These benefits stack with LDL-C reduction rather than compete with it.

Combination Rationale: Why Prescribing Both Makes Sense

Complementary risk factor control

Atherosclerotic cardiovascular disease is driven by both elevated LDL-C and elevated blood pressure. The INTERHEART study estimated that hypertension and dyslipidemia together account for more than 50% of the population-attributable risk of a first MI. Addressing one while ignoring the other leaves a major portion of residual risk untreated.

A straightforward clinical decision framework applies here. If a patient's LDL-C remains above their guideline-based target (typically <70 mg/dL for high-risk ASCVD patients per the 2018 AHA/ACC Cholesterol Guideline) despite maximally tolerated statin therapy, inclisiran is an appropriate add-on. If that same patient's blood pressure exceeds 130/80 mmHg, ACE inhibitor initiation is independently indicated. The presence of one indication does not diminish the other.

No pharmacokinetic competition

Inclisiran reaches peak plasma concentration within 4 hours of subcutaneous injection and distributes primarily to the liver within 24 to 48 hours. Its plasma half-life is approximately 9 hours, but its pharmacodynamic effect persists for 6 months because the hepatic siRNA concentration remains elevated. Lisinopril is not metabolized by the liver. It has a plasma half-life of 12 hours and acts on the vascular and renal ACE enzyme. These absorption, distribution, and elimination profiles do not intersect.

No Phase I drug-drug interaction study has identified any pharmacokinetic signal between inclisiran and any ACE inhibitor, and the FDA label for Leqvio does not list lisinopril or the ACE inhibitor class in its drug interaction section.

Shared patient population

The typical inclisiran candidate is a patient aged 50 to 75 with established ASCVD (prior MI, prior stroke, or peripheral artery disease) who remains above LDL-C target on a statin. A significant proportion of that population already carries a diagnosis of hypertension. In the ORION-10 population, hypertension was present in approximately 80% of enrolled patients. Many were on ACE inhibitors or ARBs at baseline. No safety signal emerged in that subgroup compared to the overall trial population.

Risks of Combination Use

Renal function monitoring

Both inclisiran and lisinopril exert effects on the kidney, though through distinct pathways. Inclisiran is eliminated renally, and its AUC increases approximately 1.5-fold in patients with severe renal impairment (eGFR <30 mL/min/1.73m2). ACE inhibitors reduce glomerular filtration pressure and may produce a modest rise in serum creatinine of up to 30% after initiation, which is expected and generally not a reason to stop the drug. However, in patients with bilateral renal artery stenosis or a single functioning kidney, ACE inhibitors carry a risk of acute kidney injury.

The practical implication is that clinicians should check baseline eGFR and serum potassium before starting or up-titrating lisinopril in a patient already on inclisiran. A creatinine rise >30% above baseline, or a new potassium above 5.5 mEq/L, warrants dose reduction or discontinuation of lisinopril.

Hyperkalemia risk

ACE inhibitors block aldosterone release, which reduces urinary potassium excretion. This is rarely a problem in isolation, but the risk rises with concurrent use of potassium-sparing diuretics, NSAIDs, or trimethoprim. Inclisiran itself does not affect potassium homeostasis. If a patient is on lisinopril and inclisiran together, the potassium risk comes entirely from lisinopril, not from the combination per se.

Hypotension at initiation

Lisinopril's first dose may produce a significant blood pressure drop, especially in sodium-depleted patients or those on diuretics. This risk is unrelated to inclisiran. Starting lisinopril at 5 mg daily and titrating upward over 2 to 4 weeks is standard practice to minimize symptomatic hypotension.

Cough and angioedema

ACE-inhibitor-associated cough occurs in 5 to 20% of patients (with higher rates in patients of East Asian descent) and has no relationship to concurrent inclisiran use. Angioedema, though rare, is the most serious ACE inhibitor adverse effect. If angioedema occurs in a patient on both drugs, lisinopril is the causative agent, and switching to an ARB such as losartan is appropriate. Inclisiran need not be discontinued.

Switching From Leqvio to Lisinopril: Why This Is the Wrong Frame

A common search query asks whether a patient should "switch" from Leqvio to lisinopril. This framing reflects a misunderstanding of what each drug does. Switching is appropriate when two drugs treat the same condition and one performs better or causes fewer side effects. Inclisiran and lisinopril treat different conditions.

If a clinician is considering stopping inclisiran and starting lisinopril, the question to ask first is: has the patient's primary problem changed from hyperlipidemia to hypertension? If both problems exist, the appropriate response is to add lisinopril, not substitute it. If only hypertension needs treatment and the original LDL-C rationale no longer applies (for example, the patient had secondary hyperlipidemia that has resolved), then stopping inclisiran and starting lisinopril becomes defensible.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states explicitly that LDL-C-lowering and blood-pressure-lowering therapies have additive, not competing, effects on cardiovascular event reduction.

Practical Prescribing Guidance

Starting inclisiran in a patient already on lisinopril

No washout or timing restriction applies. Inclisiran 284 mg can be given subcutaneously at the initial visit, repeated at 3 months, then every 6 months thereafter. Lisinopril continues unchanged. Check a fasting lipid panel 90 days after the first injection to confirm LDL-C response. Expect approximately 50% reduction from baseline.

Starting lisinopril in a patient already on inclisiran

Begin at 5 mg daily orally. Check blood pressure, serum creatinine, and potassium 1 to 2 weeks after initiation, then at each up-titration step. The maximum approved dose is 40 mg daily for hypertension. Target blood pressure is <130/80 mmHg per current ACC/AHA guidelines for patients with ASCVD.

Monitoring schedule on combination therapy

• Fasting LDL-C panel: at 90 days after each inclisiran injection
• Blood pressure: at every clinical encounter; home monitoring daily if available
• Serum creatinine and eGFR: at baseline, 1 to 2 weeks after lisinopril initiation, and every 6 to 12 months thereafter
• Serum potassium: same schedule as creatinine
• Liver enzymes: not routinely required for inclisiran; monitor per statin co-administration if applicable

Special Populations

Patients with chronic kidney disease

CKD is a high-frequency comorbidity in both the ORION-10 population and the ALLHAT population. ACE inhibitors slow CKD progression and reduce proteinuria, per the 2022 KDIGO CKD guideline recommendation for first-line use in CKD with albuminuria. Inclisiran's renal elimination means AUC is elevated in severe CKD, but no dose adjustment is required because the drug's hepatic mechanism is unaffected. Novartis pharmacokinetic data reported in the FDA prescribing information confirm no dose change is needed for eGFR as low as 15 mL/min/1.73m2.

Patients with diabetes

Diabetes accelerates both hyperlipidemia and hypertension. ACE inhibitors are preferred first-line agents for hypertension in diabetes because of renal-protective effects. Inclisiran's LDL-C lowering in the ORION-10 diabetic subgroup was consistent with the overall 52.3% reduction seen across the trial, with no signal of impaired glycemic control.

Patients post-MI with heart failure

A patient who has had an MI, has a reduced ejection fraction (<40%), and has residual elevated LDL-C represents the clearest argument for combination use. ACE inhibitors are class I, level A recommendations in this setting per the 2022 AHA/ACC heart failure guidelines. Inclisiran addresses the lipid burden. Using both agents together is not only acceptable, it is the guideline-concordant standard of care for this phenotype.

Cost and Access Considerations

Inclisiran carries a list price in the United States of approximately $3,300 per injection (two injections in year one, then one per year). Patient assistance programs through Novartis may reduce out-of-pocket costs for commercially insured patients. Lisinopril is generic and costs under $10 per month at most pharmacies. The total cost of combination therapy is dominated by inclisiran. Clinicians and patients should confirm insurance coverage before initiating inclisiran and explore the Leqvio patient support program if cost is a barrier.

Clinical Bottom Line

Inclisiran and lisinopril address orthogonal cardiovascular risk factors. Prescribing them together reflects guideline-concordant multi-risk-factor management, not polypharmacy excess. For a high-risk ASCVD patient with LDL-C >70 mg/dL on maximally tolerated statin therapy and blood pressure >130/80 mmHg, the combination of inclisiran 284 mg every 6 months plus lisinopril 10 to 40 mg daily targets both the atherogenic and hemodynamic drivers of recurrent events. The monitoring priority on combination therapy is renal function: check eGFR and potassium within 2 weeks of any lisinopril dose increase.